{"result": {"id": "f45488d7-821a-44ac-ba3b-945e8fbdb0da", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>STATINS<|>organization<|>Statins are a class of drugs that lower LDL-C and TG levels while increasing HDL-C, widely used as first-line treatment for hyperlipidemia)\n##\n(\"entity\"<|>ATORVASTATIN<|>organization<|>Atorvastatin is a high-intensity statin medication used to significantly lower LDL-C levels)\n##\n(\"entity\"<|>ROSUVASTATIN<|>organization<|>Rosuvastatin is a high-intensity statin medication effective at lowering LDL-C levels)\n##\n(\"entity\"<|>FLUVASTATIN<|>organization<|>Fluvastatin is a moderate-intensity statin used for cholesterol management)\n##\n(\"entity\"<|>LOVASTATIN<|>organization<|>Lovastatin is a moderate-to-low intensity statin medication)\n##\n(\"entity\"<|>PITAVASTATIN<|>organization<|>Pitavastatin is a moderate-to-low intensity statin used for lipid control)\n##\n(\"entity\"<|>PRAVASTATIN<|>organization<|>Pravastatin is a moderate-to-low intensity statin medication)\n##\n(\"entity\"<|>SIMVASTATIN<|>organization<|>Simvastatin is a moderate-intensity statin used for cholesterol reduction)\n##\n(\"entity\"<|>XUEZHIKANG<|>organization<|>Xuezhikang is a Chinese red yeast rice extract used as a low-intensity cholesterol-lowering agent)\n##\n(\"entity\"<|>CHOLESTEROL ABSORPTION INHIBITOR<|>organization<|>A class of drugs that work by blocking cholesterol absorption in the intestine, often used in combination with statins)\n##\n(\"relationship\"<|>STATINS<|>LDL-C<|>Statins are primary medications for reducing LDL-C levels in patients with hyperlipidemia<|>9)\n##\n(\"relationship\"<|>STATINS<|>TG<|>Statins can moderately reduce triglyceride levels while primarily targeting LDL-C<|>6)\n##\n(\"relationship\"<|>STATINS<|>HDL-C<|>Statins may modestly increase HDL-C levels while primarily lowering LDL-C<|>5)\n##\n(\"relationship\"<|>ATORVASTATIN<|>STATINS<|>Atorvastatin is a member of the statins drug class<|>8)\n##\n(\"relationship\"<|>ROSUVASTATIN<|>STATINS<|>Rosuvastatin is a member of the statins drug class<|>8)\n##\n(\"relationship\"<|>FLUVASTATIN<|>STATINS<|>Fluvastatin is a member of the statins drug class<|>8)\n##\n(\"relationship\"<|>LOVASTATIN<|>STATINS<|>Lovastatin is a member of the statins drug class<|>8)\n##\n(\"relationship\"<|>PITAVASTATIN<|>STATINS<|>Pitavastatin is a member of the statins drug class<|>8)\n##\n(\"relationship\"<|>PRAVASTATIN<|>STATINS<|>Pravastatin is a member of the statins drug class<|>8)\n##\n(\"relationship\"<|>SIMVASTATIN<|>STATINS<|>Simvastatin is a member of the statins drug class<|>8)\n##\n(\"relationship\"<|>XUEZHIKANG<|>STATINS<|>Xuezhikang contains natural statin-like compounds<|>7)\n##\n(\"relationship\"<|>CHOLESTEROL ABSORPTION INHIBITOR<|>STATINS<|>Cholesterol absorption inhibitors are often used in combination with statins for enhanced LDL-C reduction<|>7)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751559194, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 844, "prompt_tokens": 3170, "total_tokens": 4014, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 3072}, "prompt_cache_hit_tokens": 3072, "prompt_cache_miss_tokens": 98}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 不超过 80 cm。\n　　4. 戒烟、限酒：吸烟会损害血脂谱，导致 TG 升 高、HDL?C 降低，增加心血管疾病风险，并影响血管 功能［37］。因此，强烈建议戒烟并避免被动吸烟 。此 外，应限制酒精摄入，建议成人每日酒精摄入量不 超过 15 g［38］。\n（三）药物治疗\n　　　当通过生活方式干预无法达到降脂目标时，应  考虑药物治疗 。降脂药物可显著降低 LDL?C 水平， 且随着 LDL?C 降低幅度增大，ASCVD 事件风险降  低［39］。建议根据病情个体化选择降脂强度（表 3）。 根据作用机制，可将降脂药物分为主要降低胆固醇  和主要降低 TG 的药物。\n1. 主要降低胆固醇的药物\n　　（ 1）他汀类药物：他汀类药物是目前高脂血症  治疗的一线药物，其可有效降低混合型高脂血症患  者的 LDL?C 和 TG 水平，同时提升 HDL?C 水平［15］，且  其的心血管保护效果与降低 LDL?C 程度成正比［40］。 2019 年欧洲心脏病学会/欧洲动脉粥样硬化学会血  脂异常管理指南指出，与 TG 升高相关的 LDL?C 升\n\n\n\n中华全科医师杂志 2024 年 9 月第 23 卷第 9 期    Chin J Gen Pract, September 2024, Vol. 23, No. 9                                                                  · 911   ·\n\n\n高会增加心血管疾病风险［22］。 因此，TG 水平较高 的混合型高脂血症患者可从他汀类药物治疗中获\n表3    不同强度的降胆固醇药物治疗方案\n\n强度                                        药物及其剂量\n高强度\n（LDL?C 降幅≥50%）\n\n\n\n\n中等强度\n（LDL?C 降幅 25%~50%）\n\n\n\n\n\n\n低强度\n（LDL?C 降幅<25%）\t阿托伐他汀 40~80 mg/次，每日 1 次a\n瑞舒伐他汀 20~40 mg/次，每日 1 次\n中等强度他汀类药物联合胆固醇吸收\n抑制剂\nPCSK9 抑制剂单独或联合使用\n　小干扰 RNA 药物联合他汀类药物  阿托伐他汀 10~20 mg/次，每日 1 次 瑞舒伐他汀 5~ 10 mg/次，每日 1 次   氟伐他汀 80 mg/次，每日 1 次\n洛伐他汀 40 mg/次，每日 1 次\n匹伐他汀 2~4 mg/次，每日 1 次\n普伐他汀 40 mg/次，每日 1 次\n辛伐他汀 20~40 mg/次，每日 1 次\n血脂康 0.6 g/次，每日 2 次\n　氟伐他汀 40 mg/次，每日 1 次 洛伐他汀 20 mg/次，每日 1 次 匹伐他汀 1 mg/次，每日 1 次   普伐他汀 20 mg/次，每日 1 次 �\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>TG<|>organization<|>TG refers to triglycerides, a type of fat found in the blood that is associated with cardiovascular disease risk when elevated)\n##\n(\"entity\"<|>HDL-C<|>organization<|>HDL-C stands for high-density lipoprotein cholesterol, often referred to as 'good' cholesterol, which helps remove other forms of cholesterol from the bloodstream)\n##\n(\"entity\"<|>LDL-C<|>organization<|>LDL-C stands for low-density lipoprotein cholesterol, often referred to as 'bad' cholesterol, which can build up in the arteries and increase the risk of cardiovascular disease)\n##\n(\"entity\"<|>ASCVD<|>organization<|>ASCVD stands for atherosclerotic cardiovascular disease, a condition characterized by the buildup of plaques in the arteries)\n##\n(\"entity\"<|>PCSK9 INHIBITOR<|>organization<|>PCSK9 inhibitors are a class of drugs that help lower LDL-C levels by increasing the liver's ability to remove LDL-C from the blood)\n##\n(\"entity\"<|>SMALL INTERFERING RNA DRUGS<|>organization<|>Small interfering RNA drugs are a newer class of medications that can help lower cholesterol levels by targeting specific genes involved in cholesterol metabolism)\n##\n(\"entity\"<|>EUROPEAN SOCIETY OF CARDIOLOGY<|>organization<|>The European Society of Cardiology is a professional organization that provides guidelines for the management of lipid disorders and cardiovascular diseases)\n##\n(\"entity\"<|>EUROPEAN ATHEROSCLEROSIS SOCIETY<|>organization<|>The European Atherosclerosis Society is a professional organization focused on the study and treatment of atherosclerosis and related conditions)\n##\n(\"relationship\"<|>TG<|>HDL-C<|>TG and HDL-C are both lipid markers used to assess cardiovascular risk, with high TG and low HDL-C being associated with increased risk<|>7)\n##\n(\"relationship\"<|>LDL-C<|>ASCVD<|>Elevated LDL-C levels are a major risk factor for the development of ASCVD<|>9)\n##\n(\"relationship\"<|>PCSK9 INHIBITOR<|>LDL-C<|>PCSK9 inhibitors are used to significantly lower LDL-C levels in patients with high cholesterol<|>8)\n##\n(\"relationship\"<|>SMALL INTERFERING RNA DRUGS<|>LDL-C<|>Small interfering RNA drugs can be used in combination with statins to further lower LDL-C levels<|>7)\n##\n(\"relationship\"<|>EUROPEAN SOCIETY OF CARDIOLOGY<|>EUROPEAN ATHEROSCLEROSIS SOCIETY<|>These organizations collaborate on guidelines for the management of lipid disorders<|>6)\n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_eb2a8df2cb39a744cabbe9df47c1b32156333a9da7c860e16846d735d2877225_v2"}